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Abstract: 
Background: Dressings coated with Dialkylcarbamoyl chloride (DACC) are highly hydrophobic and 
irreversibly bind multiple types of bacteria, trapping them in the dressing and reducing the number 
of organisms at the wound surface. We aimed to assess the impact of DACC coated postoperative 
dressings on the incidence of surgical site infection (SSI) in non-implant vascular surgery patients.  
Methods: Two hundred patients undergoing non implant vascular surgery were prospectively 
recruited at a single vascular centre. The initial 100 patients had their operative wounds dressed 
with conventional dressings followed by 100 patients who received DACC coated post-operative 
dressings. Wounds were reviewed at day 5 and day 30 to determine the presence of SSI using the 
ASEPSIS scoring system. The variation in outcomes between groups was assessed using Chi-Squared 
test and Logistic regression to assess effects of other variables which may affect healing. 
 Results: Between 1st August 2015 and 29th February 2016, 120 men and 80 women were recruited. 
The mean age was 63 (range 27-97) years, 92% were current or ex-smokers and 45.5% were 
diabetic. Rate of SSI at 5 days was significantly lower in the DACC group compared to standard 
dressings (1% Vs 10%, P<0.05). There was no difference in the rates of SSI at 30 days. Logistic 
regression suggested that the type of dressing used was the most prominent predictor variable for 
the presence of early SSI (p=0.028, OR = 0.09, 95% CI: 0.01, 0.77).  
Conclusions: DACC coated dressings were associated with a significant reduction in SSI rates in the 
early post-operative period.  
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1. Introduction 
Surgical site infections (SSI) are infections occurring at the part of the body where surgery has taken 
place within 30 days of the procedure, or within one year of the procedure if a prosthetic surgical 
device was implanted (e.g. mesh, metalwork, vascular graft)1. SSI account for up to 20% of all 
hospital acquired infection and occurs in at least 5% of all surgical procedures2. Morbidity and 
mortality due to SSI can be devastating and may be preventable with appropriate strategies and 
policies in pre, intra and post-operative patient and wound care2.  One in three post-operative 
deaths are related at least in part to the presence of a SSI2 and mean additional costs incurred in 
managing a vascular SSI are estimated in the region of £8,500 per patient3.   
 
The incidence of SSI following vascular surgery is 10-15%, rising to 30% in trials specifically 
monitoring SSI as an outcome4, 5. This high incidence is thought to relate to the high rates of co-
morbidities, concurrent smoking, diabetes and groin surgery in vascular patients. SSI in vascular 
surgery are potentially devastating for patients, with 30-40% of SSI in lower limb bypass graft 
infections resulting in a major amputation6 and over one third of all post-operative deaths being  
attributable, at least in part, to an SSI2. Less severe SSI still impact upon patients’ wellbeing and 
quality of life7, 8. The hospital costs of SSI are significant with estimates between £1500 and £10,000 
per patient episode in vascular surgery 3, 9[figures updated for 2016 equivalence10]. Costs are 
attributable to extended hospital stays, need for re admissions and reoperations, drug treatments, 
increasingly complex wound management and dressing systems, and high demands on inpatient and 
community nursing staff. Any strategies to reduce SSI must be investigated for the benefit of 
patients and also to ensure the best use of limited surgical and healthcare resources.    
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Post-operative wound dressings act to absorb exudates and protect the wound from the external 
environment until epithelialisation occurs. A huge range of postoperative dressing options exist, 
however a 2014 Cochrane review and meta-analysis, which examined data from 20 randomised 
controlled trials, found no evidence to suggest that any one dressing type was more effective at 
reducing SSI than any other11. 
 One newer technology not included in this review was the use of Dialkylcarbamoyl chloride (DACC) 
as a coating on dressing surfaces. DACC is a highly hydrophobic fatty acid derivative which has 
recently been incorporated as a coating to the wound contact surface of dressings. Most 
microorganisms responsible for SSIs have hydrophobic cell surfaces12, 13 and when these organisms 
come into contact with DACC they irreversibly bind via a hydrophobic interaction with the dressing, 
and are then removed from the wound bed at the next dressing change. This removal of organisms  
reduces the bioburden at a wound surface14, thus theoretically preventing the ingress of organisms 
into the wound and reducing SSI rates.  
 
The aim of this study was to undertake a prospective comparative evaluation of the impact of DACC 
coated post-operative dressings on the rate of SSI in patients undergoing open non implant vascular 
surgery, in order to inform the future design of a fully-powered randomised controlled trial. 
2. Methods 
This was a prospective, non-randomised comparative study in a single vascular surgery centre. A 
total of 200 participants were recruited, with the initial 100 participants receiving a variety of inert, 
standard surgical dressings as per the routine clinical practice of the surgeons undertaking the 
procedure.  The second group of 100 participants received DACC coated dressings (Leukomed® 
Sorbact® – BSN Medical, Hull UK). 
2.1 Patients  
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All adult patients undergoing clean or clean contaminated non-implant vascular surgical procedures 
were considered for inclusion into the study. Patients undergoing implant-containing vascular 
surgery were excluded due to the length of time needed for follow-up. Exclusion criteria included 
known allergy to the DACC dressing components and patients already undergoing treatment with 
antibiotics.  Antibiotic prophylaxis was used as per standard operating procedures. 
2.2 Interventions 
Procedures were undertaken by or under the supervision of seven vascular consultants and all other 
aspects of peri-operative care remained unchanged between cohorts.  All dressings were applied in a 
sterile fashion in theatres following wound closure and remained in situ until wound review was 
undertaken prior to discharge or earlier if required based on clinical need. Standard or DACC coated 
dressings were continued for the duration of dressing use at that wound site.  All patients were 
discharged home with extra wound dressings to ensure like-for-like dressing changes in the 
community. 
2.3 Outcomes 
To assess wound healing we used the ASEPSIS scoring system, which utilises  seven clinical 
parameters to describe satisfactory wound healing (score <10), impaired wound healing (score 11-
20) and SSI (score > 21)15.  
The primary outcome for this study was the presence of SSI (ASEPSIS wound score >21). Secondary 
outcomes included evidence of satisfactory healing (ASEPSIS score < 10). Wound assessments were 
performed on day 5-7 and on day 30. During the assessments, any dressings were removed and a 
short patient interview and review of patient case notes and prescription chart undertaken to allow 
comprehensive recording of all wound complications and ASEPSIS score.  
2.4 Statistical analysis 
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Data was collated into IBM SPSS (IBM SPSS corporation version 22, Rochester- United States) to 
facilitate statistical analysis. Data is presented descriptively using mean (sd) or n (%) for each group. 
The groups were compared using chi-square tests or fishers exact tests for categorical data and t-
tests for continuous data (e.g. age). The primary outcome, SSI, was dichotomised into presence or 
absence of infection and statistical differences between groups were compared using a chi-square 
tests. In order to measure the association level, crude odds ratio (OR) and the 95% corresponding 
test-based confidence interval (CI) were calculated.  A logistic regression analysis was undertaken to 
control for the effects of other variables which might be expected to influence healing. A p-value of 
<0.05 was considered statistically significant. 
3. Results 
200 patients were recruited from 1st August 2015 to 29th February 2016, 120 men and 80 women, 
with a mean age of 63 (range 27-97) years. Each group had 100 patients. Comparative data for the 
two groups is summarised in table 1.  
Less patients had SSI in the DACC coated group than the standard group at 5-7 days (1/100 and 
10/100 respectively, OR = 0.09 (95% CI: 0.01, 0.072, p= 0.005). In those remaining at risk, there was 
no difference in SSI at the 30 day wound assessment (9/99 and 9/90, p=0.832). There was no 
difference in adequate wound healing at any time. ASEPSIS scores recorded for all wounds are 
summarised in table 2.   
For SSI at day 5-7, the single incident of SSI in the DACC dressing group required 7 days of IV 
antibiotics. In the non-DACC group, all 10 patients with SSI at day 5-7 were treated with antibiotics. 2 
of these required IV antibiotics, one for 21 days in total. The other 8 patients were treated with oral 
antibiotics, with 5/8 treated for 14 days total. At 30 days, there was no significant difference in 
readmission rates due to SSI between the two groups (7/99 and 9/90, p=0.470). 
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Logistic regression was performed to control for the effects of recorded variables which would be 
expected to impact upon the risk of SSI as listed in Table 3. Seven potential confounding variables 
were included in the model16. After regression analysis, the type of dressing used remained the most 
prominent predictor in early surgical site infection (p=0.028) with an odds ratio of 0.09 (95% CI: 0.01, 
0.77).  
 
4. Discussion 
This small prospective comparative trial suggests that DACC coating may reduce the rate of SSI in 
non-implant vascular surgery patients. Prior in-vitro evidence strongly supports the proposed 
mechanism of action by which DACC might be expected to limit ingress of bacteria into incision 
wounds12, 13, 17.  DACC coated dressings act by trapping and physically removing bacteria, rather than 
being bactericidal, which in the context of wider societal concerns regarding antibiotic resistance 
make this action particularly attractive as a novel intervention as the development of bacterial 
resistance is less likely. They have been shown to bind to organisms that are antibiotic resistant in 
vitro17. Results of in-vivo application of DACC coated dressings in chronically infected wounds have 
also been promising both in terms of bio-burden reduction and enhanced clinical evidence of 
healing18-21.  Equally, no absorption of DACC into the wound surface is known to occur and no 
evidence to date has reported any adverse effects to its use, allowing its potential application to all 
patient groups.    
This study was intended as a pilot to examine the possible effectiveness of DACC impregnated 
dressings as a prophylactic measure in reducing SSI rate and was able to show a significant reduction 
in incidence of SSI in a cohort of clean and clean contaminated non-implant vascular surgery with 
their use. These results are in keeping with recently published evidence supporting the use of DACC 
coated dressings as prophylaxis against SSI in fit and well patients undergoing caesarean section22.  
The maximal protective effect appears to be in the early post perioperative period, prior to the 5-7 
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day assessments. The timing of the apparent action reported in these results appears logical since 
the mechanism of action of DACC would be prevention of ingress of bacteria into freshly incised 
wounds which have yet to reepithelialise. Logistic regression suggested a significant impact of the 
dressings for all instances of SSI when controlling for potential confounding variables expected to 
impact healing, such as smoking and diabetes.  
4.1 Limitations of the study 
There were several potential sources of bias within this study. The nature of the study design was as 
an exploratory proof of concept study prior to an intended randomised trial. Although patients were 
not randomised, groups were well matched for most variables.  There is the possibility that 
introducing a study, or a study dressing, reduces the rate of measured SSI through observer bias or 
through bias of the study participant (the so-called Hawthorne effect23, 24). However, although the 
subjective aspects of the ASEPSIS scoring system were undertaken by a study clinician, treatment for 
infection, antibiotic use, and infection recorded in the patient case notes were contemporaneous 
and recorded by the patients’ main care team. Patient reported outcomes were not included in the 
final analysis. Study follow up, at 5-7 days and 30 days, was standardised across both cohorts, so any 
Hawthorne effect should be seen in both groups.  
A further source of bias was the lack of blinding. Leukomed® Sorbact®, the DACC-coated dressing in 
the study, contains a green colouring to the wound contact layer in order to identify it as a DACC-
coated dressing (Shown in Figure 1). Because of this, blinding is difficult, though not impossible to 
achieve in any trial studying its effects, leading to the open label nature of this study. Future 
randomised studies into DACC-coated dressings should make use of a wound assessor that is blind to 
the dressing type used, after removing and disposing of dressings in opaque bags. 
5. Conclusion 
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SSI is a significant problem which is likely to rise as increasing numbers of surgical procedures are 
performed in an ageing and co-morbid population.  Results reported from this study support a 
growing body of evidence, including a recent systematic review25, that DACC coated hydrophobic 
dressings have effects in preventing SSI in a number of different patient groups and may have a 
significant role in future surgical wound management. However, an adequately powered 
randomised controlled trial comparing DACC coated and conventional dressings is warranted and is 
now in preparation to provide the robust evidence essential prior to this technology being adopted 
into routine practice. 
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Legends for tables and figures 
Table 1: Participants demographics, ASA grades and surgical procedure undertaken in standard 
and DACC coated dressing groups. Two tailed P values reported from Student t tests and Chi-
square test with Yates correction, ** signifies a significant difference between patient groups.  
 
Table 2: Results of ASEPSIS scores at assessments throughout study. Two tailed P values 
reported from Chi-square test with Yates correction, ** signifies significant difference between 
patient groups. 
 
Table 3. Potential confounders to SSI included in Logistic regression. Type of surgery is divided 
into treatment for critical limb ischaemia vs other vascular surgery (** = p<0.05, df = degrees of 
freedom, Sig.= significance, OR = odds ratio, CI = confidence interval, BMI = Body mass index, 
SSI = Surgical site infection, ASA = American Society of Anaesthesiologists) 
 
Figure 1: Photographs of Leukomed® Sorbact®, the DACC-coated dressing used in the trial, 
against a white background. The coloured nature of the wound contact layer is demonstrated. 
 
 
